Condition: Active Ulcerative Colitis · Sponsor: Hoffmann-La Roche
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
This description comes directly from the study's public registry record.
Reference Study ID Number : GA46438 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Erick H. Alayo Medical Corporation - Gastro SB Clinic | Chula Vista, California, United States | Recruiting |
| Allied Biomedical Research Institute, Inc | Miami, Florida, United States | Recruiting |
| Gastro Health Research | Miami, Florida, United States | Recruiting |
| Charite Research Organisation GmbH | Berlin, Germany | Recruiting |
| Royal Liverpool University Hospital | Liverpool, United Kingdom | Recruiting |
| University College London Hospitals | London, United Kingdom | Recruiting |
| Royal Victoria Infirmary | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07665723